Revenue - Additional Information (Details) - USD ($)			1 Months Ended		3 Months Ended		6 Months Ended
		Dec. 17, 2021	Jan. 31, 2022	Dec. 31, 2021	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties, license and other revenues	[1]				$ 310,000	$ 354,000	$ 567,000	$ 619,000
Accounting Standards Update 2014-09 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Remaining performance obligations					31,600,000		31,600,000
Expected convertion to revenue by 2026					31,600,000		31,600,000
Contract Liabilities [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties, license and other revenues							30,000	$ 87,000
Roche Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment		$ 50,000,000	$ 50,000,000	$ 50,000,000
Roche Agreement [Member] | Upfront license fees [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment			$ 50,000,000				50,000,000
Collaborative Arrangement [Member] | Accounting Standards Update 2014-09 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenues					$ 27,700,000		$ 27,700,000

[1] Included within royalties, license and other revenues recognized for the six months ended June 30, 2024 and 2023, was $30,000 and $87,000, respectively, that was included within deferred revenues as contract liabilities as of January 1, 2024 and 2023, respectively.